Morgan Stanley
-
-
Concerns from some fund managers about the terms of Altice’s new €2.5bn-equivalent bond were swamped by orders from other investors eager to bag single-B paper with a big coupon from a core high yield issuer. After a series of successful investor push-backs on deal terms, the debt laden French telecom proved this week that borrowers still can walk away with loose covenants, writes Victor Jimenez. -
Wall Street heavyweights returned in force to the dollar market with a string of multi-billion dollar trades after posting strong second quarter earnings.
-
The World Bank is keen to bring a euro benchmark this year, having been absent from that segment for nearly two years. The supranational this week made a triumphant return to dollars, setting a 2018 record for the tightest swap spread on a three year dollar benchmark so far.
-
Shanghai Fosun Pharmaceutical Group bagged HK$2.6bn ($331m) from an H-share placement on Wednesday, its first capital raise in more than a year.
-
Bankers marketing the latest crop of IPOs from China’s technology sector got their game face on this week amid escalating fears of a trade war with the US.
-
Ascletis Pharma is in the market with the first biotechnology IPO in Hong Kong following the bourse’s historic change in listing rules.
-
Goldman’s new CEO David Solomon has a lot in his in-tray, not least a resurgent Morgan Stanley that has firmly hit its stride, writes David Rothnie.
-
World Bank on Wednesday returned following an eight month absence in dollar benchmark funding to print the tightest spread on a three year dollar deal from an SSA this year.
-
The San Francisco Public Utilities Commission (SFPUC) is looking for international buyers of its green bonds for the first time as it prepares a roughly $402m new issue.
-
HDFC Asset Management is gunning for up to Rp28bn ($408m) from its IPO in India after setting the final price guidance for the offering.
-
Chinese firm Ascletis Pharma has launched bookbuilding for a HK$3.58bn ($456.9m) IPO, the first company to take advantage of the Hong Kong Stock Exchange’s new biotechnology-friendly listing regime.
